LIPELLA PHARMACEUTICALS INC.
LIPELLA PHARMACEUTICALS INC. (LIPO): 4 pipeline candidates · ~6 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.2 months
D/E 0.58 · 0% dilution
Lead: Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for LIPELLA PHARMACEUTICALS INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$275K
Cash
$1.9M
Quarterly Burn
$926K
Runway
6.2 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in LIPELLA PHARMACEUTICALS INC.'s pipeline?
LIPELLA PHARMACEUTICALS INC. (LIPO) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is LIPELLA PHARMACEUTICALS INC.'s lead drug candidate?
LIPELLA PHARMACEUTICALS INC.'s most advanced tracked candidate is lp-10 (Phase 2) for Oral Lichen Planus.
What is LIPELLA PHARMACEUTICALS INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LIPELLA PHARMACEUTICALS INC. has approximately 6.2 months of cash runway.
What is LIPELLA PHARMACEUTICALS INC.'s market capitalization?
LIPELLA PHARMACEUTICALS INC.'s market capitalization is approximately $275K.
Who is the CEO of LIPELLA PHARMACEUTICALS INC.?
Dr. Jonathan Kaufman M.B.A., Ph.D. is the chief executive officer of LIPELLA PHARMACEUTICALS INC. (LIPO).
Get the full picture on LIPELLA PHARMACEUTICALS INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.